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A B S T R A C T   
Background: Rifampicin resistant tuberculosis (RR-TB) was frequently detected in Suriname after the introduction 
of Xpert MTB/RIF in 2012. Subsequent phenotypic drug-susceptibility testing (DST) was not conclusive at that 
moment, while RR-TB patients treated with first-line tuberculostatics had good treatment outcome. In our study, 
we analysed this interesting observation. 
Methods: We collected demographic and clinical characteristics and treatment outcome of TB patients from May 
2012-December 2018 and performed a univariate and multivariate analysis to assess possible associations with 
resistance to rifampicin. Secondly, we conducted whole genome sequencing on all available Mycobacterium 
tuberculosis isolates that had a rifampicin resistance in the Xpert MTB/RIF test and performed phenotypic DST on 
selected isolates. 
Findings: RR-TB was detected in 59 (9.6%) patients confirmed by Xpert. These patients were treated with 
rifampicin-containing regimens in most (88%) of the cases. In all 32 samples examined, a D435Y mutation in the 
rpoB gene was identified; only one isolate revealed an additional isoniazid mutation. Phenotypic DST indicated 
low-level rifampicin resistance. In multivariate analysis, the Creole ethnicity was a factor associated with 
rifampicin resistance (aOR 3.5; 95%CI 1.9–6.4). The treatment success rate for patients with RR-TB (78.0%) was 
comparable to the treatment outcome in non-RR-TB patients 77.8%. 
Interpretation: This study confirms a low-level rifampicin mono-resistance in TB patients of Suriname. These 
patients could benefit from a first-line regimen with high dose rifampicin (or rifabutin), rather than from the 
lengthy treatment regimens for rifampicin-resistant and multi-drug resistant TB, a concept of stratified medicine 
also advocated for the treatment of TB. 
Funding: None.   
1. Introduction 
Globally, an estimated 10 million people developed tuberculosis (TB) 
in 2018; half a million of them had rifampicin-resistant (RR) TB [1], of 
which 78% had also confirmed resistance to isoniazid (INH), and were 
hence classified as multidrug-resistant (MDR) TB. 
The last decade brought large improvements in the diagnosis and 
treatment of RR/MDR-TB.[2] For instance, rifampicin resistance can 
now be diagnosed with rapid molecular tests and new effective second- 
line drugs as bedaquiline and linezolid, are now included in injection- 
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free treatment regimens recommended by the World Health Organiza-
tion (WHO).[3] The new diagnostic tests and drugs have become 
available to low and middle-income countries at special pricing schemes 
e.g. through support of the Global Fund to fight AIDS, TB and Malaria. 
Despite these advances, globally only 51% of patients with confirmed TB 
were tested for rifampicin resistance in 2018. Moreover, only 33% of all 
estimated RR/MDR-TB patients were enrolled in treatment, with a 
treatment success rate of 56%.[1] 
Suriname is a country with a multi-ethnic population of 575,991 in 
2018 (https://data.worldbank.org/country/Suriname) consisting of 
Hindustani (27%), Maroon (22%), Creole (16%), Javanese (14%), mixed 
(13%) or people with other ethnic background (8%) 
(https://statistics-suriname.org/nl/censusstatistieken-2012–2/). The 
TB notification rate was 30 per 100,000 population in 2018; WHO 
estimated the TB incidence at 38 per 100,000.[1] Before 2012, drug 
susceptibility testing (DST) was not routinely available in Suriname. 
Samples were sent abroad, and only two MDR-TB patients were diag-
nosed from 2005 till 2011. In May 2012, the Xpert® MTB/RIF test 
(Cepheid, Sunnyvale, CA, USA) was introduced in Suriname. The un-
expected high proportion of rifampicin-resistant Xpert results has puz-
zled national and international TB experts for several years. Phenotypic 
drug susceptibility testing (DST) performed by one international labo-
ratory in 2012 showed susceptibility to rifampicin, while re-analysis by 
the supranational reference laboratory several years later showed 
rifampicin resistance in these strains.[4] In 2018, 12.4% of confirmed 
cases in Suriname had RR-TB, which is the highest proportion in the 
WHO Region of the Americas.[1] 
This study aims to identify characteristics of the RR-TB patients in 
Suriname, understand the resistance pattern found, search for similar 
strains in the Netherlands, a country with strong historical ties to Suri-




In Suriname, TB patients are mandatory reported to the National 
Tuberculosis Program (NTP), which maintains an electronic national TB 
register. In our study, we included TB patients who were notified be-
tween May 2012 and December 2018. Patients were treated according to 
National Treatment Guidelines, which had been based on the 2010 
Caribbean TB guidelines [5], with a standard regimen of isoniazid, 
rifampicin, ethambutol and pyrazinamide. Streptomycin and/or cipro-
floxacin were added to the regimen in some patients who had previous 
TB treatment or RR-TB. Patients treated with a regimen without rifam-
picin were treated for 12–18 months. Patients, including those with RR- 
TB, were not actively followed up after treatment completion. 
The following data were obtained from the register: sex, age, 
ethnicity, site of disease, smear results, Xpert results, drug-resistance, 
case type (new or previously treated), current TB treatment regimen, 
co-morbidities (HIV, diabetes mellitus), illicit drug use (marihuana or 
hard drugs) and treatment outcome. Treatment outcomes (including RR- 
TB) were based on the definitions and reporting framework for drug- 
sensitive TB [6], e.g. failure was defined if the sputum was microscop-
ically or culture positive after 5 months treatment and cure if the smear 
was microscopically negative after 6 months treatment. A positive smear 
was graded as previously described.[7] 
We compared demographic and clinical characteristics of Xpert- 
confirmed rifampicin-sensitive and rifampicin-resistant TB patients. 
Data were analysed with SPSS version 24 (SPSS, Inc., Chicago, IL, USA), 
including a univariate analysis to estimate the Odds Ratio (OR) and 95% 
Confidence Intervals (95%CI) and a multivariate regression analysis 
including those variables that attained a P value < 0.25 in the univariate 
analysis. 
2.2. Mycobacterium tuberculosis isolates Suriname 
In Suriname, samples of all TB patients are sent to the Central Lab-
oratory, which accommodates the national TB reference laboratory, and 
performs culture (Löwenstein Jensen) and strain identification (SD 
BIOLINE TB Ag MPT64). Cultured M. tuberculosis isolates are stored at 
minus 80◦ Celsius. 
In 2018, 32 stored Xpert rifampicin-resistant Mycobacterium tuber-
culosis isolates were re-cultured and sent to the National Tuberculosis 
Reference Laboratory of the National Institute for Public Health and the 
Environment (RIVM) in the Netherlands for further analysis. These 
isolates were from patients diagnosed in 2012 (n = 4), 2013 (n = 4), 
2014 (n = 10), 2015 (n = 8), 2017 (n = 3) and 2018 (the first three RR- 
TB patients in that year). Rifampicin-resistant M. tuberculosis isolates 
from 2016 were not available for analysis. At the RIVM, whole genome 
sequencing (WGS) was applied to detect mutations associated with 
resistance and to determine the genetic distance between the isolates, as 
a proxy for epidemiological links between cases. Additionally, reverse 
line blot assays (GenoType MTBDRplus® Hain Lifesciences, Nehren, 
Germany) and phenotypic DST were performed on selected isolates. 
2.3. Similar isolates in the Netherlands 
We searched the Dutch TB laboratory database at the RIVM for iso-
lates with the same mutation found in Suriname, and obtained data from 
the Dutch National TB Register of patients infected with M. tuberculosis 
isolates with this mutation. Isolates that were possibly identical with the 
strain found in Suriname were subjected to WGS. 
2.4. Ethical consideration 
Ethical approval for this study was obtained from the Human Sci-
entific Research Ethic Committee of the Ministry of Health of Suriname. 
The Dutch National TB Registration Committee approved the use of the 
data from the Netherlands for this study. 
3. Results 
3.1. Patients 
Between May 2012 and December 2018, a total of 978 TB patients 
were notified to the NTP in Suriname. The male–female ratio was 2.5 
(696 male patients; 71%) with a median age of 42 years (interquartile 
range [IQR] 29–53). Patients’ ethnicity was mostly Creole (32%), fol-
lowed by Maroon (16%), Hindustani (15%) or mixed ethnicity (16%). 
Eighty-six percent (n = 838) of the patients had pulmonary TB; 599 had 
a smear positive sputum with microscopy (71% of pulmonary TB pa-
tients). Xpert was positive in 64% (n = 623) of the patients; whilst 
negative or not done in the remaining 36% (n = 355) of patients. 
Rifampicin resistance was determined in 59 (9.5%) of Xpert-positive 
patients (Table 1). Nine percent of patients (n = 91) were previously 
treated for TB. HIV status was known in 939 patients (96%) and HIV co- 
infection was present in 23% (n = 218) of tested patients. Diabetes 
mellitus was prevalent in 13% of the patients (n = 123) and illicit drug 
use was reported in 24% (n = 239) of the patients. 
In univariate analysis, RR-TB patients were significantly more often 
in the age group 45–60 years (reference 15–24 years), had the Creole 
ethnicity, were previously treated for TB, had HIV co-infection and had 
documented illicit drug use, compared to patients with rifampicin- 
sensitive TB. Pulmonary RR-TB patients had more frequently 
microscopy-positive sputum smears (97%; 56/58) than pulmonary 
rifampicin-sensitive-TB patients (88%; 480/548) (p = 0.07). In multi-
variate analysis, patients with RR-TB were significantly more often of 
Creole ethnicity (aOR 3.5) (Table 2). HIV and illicit drug use were 
confounding factors related to Creole ethnicity: 32% (64/198) of all 
Xpert-positive Creole TB patients were HIV co-infected and 42% (84/ 
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198) had documented illicit drug use versus respectively 12% and 23% 
of patients with other ethnicities. 
Treatment outcome was successful (cured/completed) in 74.6% of 
all TB patients, in 77.8% of patients with Xpert rifampicin-sensitive TB 
and in 78.0% of patients with Xpert diagnosed RR-TB (Table 3). Second- 
line drugs (ciprofloxacin (n = 15), streptomycin (n = 2), or both cip-
rofloxacin and streptomycin (n = 20)) were added to the standard first- 
line treatment regimen in 37 patients; 21 of these patients had 
rifampicin-sensitive TB (4% of all rifampicin-sensitive TB patients) and 
16 had RR-TB (27% of all RR-TB patients). Fifty-two (88%) RR-TB pa-
tients were treated with rifampicin-containing first-line regimens (11 
out 52 were also treated ciprofloxacin and/or streptomycin), five (8%) 
patients were treated with the first-line drug regimen without rifampicin 
but to which was added ciprofloxacin and/or streptomycin, and two 
(3%) patients did not start treatment. 
In total, 12 RR-TB patients were previously treated for TB (one 
person was treated for TB two times and another person three times) 
(Table 4). Three of these patients restarted treatment after discontinuing 
the treatment in the first episode (two had RR-TB in the first episode, the 
other one had a diagnosis before 2012) and nine completed treatment in 
the first episode (two diagnosed with RR-TB before, one with rifampicin- 
sensitive TB, five had a TB diagnosis before 2012 with an unknown 
resistance pattern, and in one patient DST was not done in the previous 
episode). 
3.2. Whole genome sequencing (WGS) and additional laboratory tests 
WGS revealed a D435Y mutation in the rpoB gene in all 32 
rifampicin-resistant M. tuberculosis isolates. One isolate had an addi-
tional resistance mutation in the inhA gene S94A, but not in the more 
common inhA promoter gene region, and by definition labelled as MDR. 
None of the remaining 31 isolates had additional first-line drug 
resistance-associated mutations in the katG, inhA, fabG1, ahpC, embA, 
embB, pncA or rpsA genes. The 32 isolates were all linked together by 
WGS in one genetic cluster with ≤ 12 single nucleotide polymorphisms 
(SNPs) difference to each other. 
The GenoType MTBDRplus analysis of 14 isolates (from 2015 to 
2018) showed loss of hybridization of wild type probes 3 and 4, and no 
hybridization of the known and most frequently reacting mutation 
probes. Phenotypic DST, done by the Middlebrook 7H10 agar proportion 
method [8], indicated a MIC (minimal inhibitory concentration) for 
rifampicin of 1–5 mg/L, known as low level resistance (cut-off is 1 mg/L) 
and showed susceptibility to rifabutin for the three isolates tested (all 
patients diagnosed in 2018). These three isolates were also tested in the 
MGIT and were found susceptible to rifampicin. 
3.3. D435Y isolates and patients in the Netherlands 
The Dutch national TB laboratory database contained 15 
Table 1 
Total number of tuberculosis (TB) and Xpert MTB/RIF rifampicin-resistant TB patients in Suriname, May 2012 - December 2018.  
Year Number of TB 
patients 
Number of patients with confirmed 
diagnosis by Xpert MTB/RIF 
Number of rifampicin-resistant TB (by 
Xpert MTB/RIF) 
Proportion Xpert MTB/RIF-positive patients with 
rifampicin resistant TB 
May-December 
2012* 
98 74 8  10.8 
2013 141 91 8  8.8 
2014 158 112 10  8.9 
2015 150 78 8  10.3 
2016 116 80 4  5.0 
2017 136 83 8  9.6 
2018 179 105 13  12.4 
Total 978 623 59  9.5 
Abbreviations: TB = tuberculosis 
* The total number of tuberculosis patients in the year 2012 (January-December) was 135. 
Table 2 
Demographic and clinical factors of tuberculosis patients with positive Xpert MTB/RIF results in Suriname, May 2012 -December 2018.   
Patients with rifampicin sensitive TB (n = 564) Patients with rifampicin-resistant TB (n = 59) Unadjusted odds ratio Adjusted odds ratio 
Characteristics N % N % OR CI OR CI 
Male sex 420  74.5 48  81.4 1.5 0.8–3.0 0.9 0.4–2.0 
Age group         
0–14 years 12  2.1 2  3.4 4.0 0.7–23.0 5.9 1.0–35.3 
15–29 years 121  21.5 5  8.5 1  1  
30–44 years 167  29.6 16  27.1 2.3 0.8–6.5 1.4 0.5–4.2 
45–59 years 187  33.2 32  54.2 4.1 1.6–10.9 2.4 0.9–6.8 
60 years and above 77  13.7 4  6.8 1.3 0.3–4.8 1.0 0.3–4.1 
Ethnicity*         
Creole 161  28.5 37  62.7 1  3.5 1.9–6.4 
Other than Creole ethnicity (403)  (71.5) (22)  (37.3) (4.2) (2.4–7.4) 1  
Maroon 87  15.4 5  8.5 0.3 0.1–0.7   
Mixed 98  17.4 5  8.5 0.2 0.1–0.6   
Hindustani 85  15.1 7  11.9 0.4 0.2–0.8   
Javanese 64  11.3 4  6.8 0.3 0.1–0.8   
Amerindian 58  10.3 1  1.7 0.1 0.0–0.6   
Other/Unknown 11  2.0 0  0.0 0.0    
Pulmonary TB 548  97.2 58  98.3 1.7 0.2–13.0   
Previous TB treatment 46  8.2 12  20.3 2.9 1.4–5.8 2.0 1.0–4.3 
HIV positive 95  16.8 20  33.9 2.5 1.4–4.5 0.8 0.4–1.5 
Diabetes mellitus 98  17.4 7  11.9 0.6 0.3–1.5   
Illicit drug use 155  27.5 27  45.8 2.2 1.3–3.8 0.7 0.4–1.2 
Abbreviations: CI = 95% confidence interval; HIV = human immunodeficiency virus; OR = odds ratio; TB = tuberculosis 
* Creole: descendant of African slaves that may also have European and other ancestors; Maroon: descendant of escaped African slaves; Hindustani: descendant of 
contract laborers from what was then British India; Javanese: descendant of contract laborers predominantly from Java, Indonesia [33]. 
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M. tuberculosis isolates with the same D435Y mutation found in Suri-
name (Table 5). The isolates were from patients born in Europe (n = 6), 
Suriname (n = 5), Africa (n = 3) and Asia (n = 1). The isolates from the 
10 non-Suriname-born patients were resistant to isoniazid and 8 out of 
10 susceptible to rifabutin; patients were treated accordingly (Table 5). 
The isolates from the 5 Suriname-born patients were all susceptible to 
isoniazid, rifampicin-susceptible in two cases (both tested by MGIT- 
DST) and low-level rifampicin-resistant in three cases (one patient 
with recurrent TB was counted twice; all these isolates were tested by 
Middlebrook 7H10). The two patients with rifampicin-sensitive TB 
completed standard first-line treatment, including standard dose 
rifampicin. One RR-TB patient was treated for 6 months with a first-line 
regimen, containing rifabutin instead of rifampicin, to which the strain 
was susceptible. The patient diagnosed twice with RR-TB first completed 
12 months treatment with isoniazid, ethambutol, moxifloxacin and 2 
months pyrazinamide, but developed RR-TB again after ten years. This 
second time, he was treated for 6 months with the first-line drug 
regimen, with rifabutin, to which the strain was susceptible, replacing 
rifampicin. Genotypically, all five M. tuberculosis isolates of the 
Suriname-born patients in the Netherlands clustered in the WGS with 
those of the 32 patients diagnosed in Suriname. 
4. Discussion 
Our study shows that rifampicin-resistant TB in Suriname is caused 
by a M. tuberculosis isolate with a D435Y mutation in the rpoB gene, 
known to be associated with a low-level resistance for rifampicin.[9–12] 
Only one patient had also an uncommon mutation coding for isoniazid 
resistance and hence had MDR-TB; all other RR-TB patients had rifam-
picin mono-resistant isolates. RR-TB patients were mainly treated with 
rifampicin-containing regimens. Treatment outcome was similar in pa-
tients with rifampicin-sensitive and RR-TB, with a successful treatment 
completion rate of 78% in both groups. Patients were not actively fol-
lowed up after treatment completion and only identified with recurrent 
TB if they presented with symptoms and were diagnosed. Patients with 
isolates harbouring the D435Y mutation were also identified in the 
Netherlands, but only the patients born in Suriname had an infection 
with a rifampicin mono-resistant strain. These patients had been treated 
either as rifampicin-sensitive TB, or with first-line regimens including 
rifabutin. 
Rifampicin resistance in M. tuberculosis is mostly caused by an un-
disputed mutation in the rpoB gene, most commonly the S450L muta-
tion. The D435Y mutation described in our study is a mutation with 
disputed drug-resistance and characterised by a substitution of the 
amino acid asparagine (Asp/D) by tyrosine (Tyr/Y) in codon 516.[13] In 
the previous classification with E. coli codon numbering, this mutation 
was known as D516Y or GAC516TAC and renamed with the H37Rv 
numbering to D435Y. Studies investigating the accuracy of current 
laboratory tests to identify resistance in D435Y mutation isolates 
concluded that low level rifampicin resistance is often missed in the 
single point concentration MGIT-DST, while it is identified by MIC 
methods like Middlebrook 7H10 and Löwenstein-Jensen and by mo-
lecular test such as Xpert and MTBDRplus[9–11,14] Other studies 
concluded that the rifampicin resistance is often borderline or low level. 
[12,15–19] Almost all studies concluded that isolates with a D435Y 
mutation are susceptible to rifabutin.[10,15–17,20] 
The Suriname NTP had difficulties in the interpretation of the 
rifampicin resistance detected by the Xpert test. In 2012, six Xpert 
rifampicin-resistant M. tuberculosis isolates were transported to an in-
ternational laboratory, where MGIT-DST and 7H10 Middlebrook MIC 
method revealed susceptibility to rifampicin in all isolates. In 2016, the 
supranational reference laboratory of Massachusetts re-analysed these 
isolates using an agar proportion method and found rifampicin resis-
tance in four of the six isolates. Furthermore, it performed PCR- 
mediated direct DNA sequencing of the rpoB gene on these six isolates 
and on 10 lysates of Xpert rifampicin-resistant M. tuberculosis isolates 
from 2014, revealing the D435Y mutation in 14 of the 16 samples.[4] 
WHO’s treatment advise on rifampicin mono-resistant TB has 
changed over time. In the first guidelines on drug-resistant TB, a 12–18 
months regimen with isoniazid, ethambutol and a fluoroquinolone, and 
Table 3 
Treatment results of tuberculosis patients in Suriname, May 2012 - December 























N % N % N % 
Successful (cured/completed) 730  74.6 439  77.8 46  78.0 
Treatment failed 2  0.2 2  0.4 1  1.7 
Died 136  13.9 59  10.5 4  6.8 
Lost to follow-up 68  7.0 42  7.4 6  10.2 
Treatment stopped (medical reason) 21  2.1 5  0.9 1  1.7 
Not evaluated* 21  2.1 17  3.0 1  1.7 
Total 978  564  59  
Abbreviations: TB = tuberculosis 
* Not evaluated: patients transferred out and patients whose treatment 
outcome was unknown. 
** 41 rifampicin-resistant tuberculosis (RR-TB) patients were treated with 
first-line drugs including standard dose rifampicin; 36 (87.8%) had a successful 
treatment outcome (median days treatment: 198; interquartile range [IQR] 
187–222). 11 RR-TB patients were treated with first-line drugs including stan-
dard dose rifampicin, and in addition with ciprofloxacin (n = 4), streptomycin 
(n = 1) or ciprofloxacin and streptomycin (n = 6); 6 (55%) had a successful 
treatment outcome (median days treatment: 289; IQR 280–304). Five RR-TB 
patients were treated with first-line drugs without rifampicin, and in addition 
with ciprofloxacin (n = 2) or ciprofloxacin and streptomycin (n = 3); 4 (80%) 
had a successful treatment outcome (median days treatment: 381; IQR 
362–447). Two RR-TB patients did not start treatment: one died before treat-
ment and one was not evaluated. 
Table 4 
Patients with rifampicin-resistant tuberculosis in Suriname who were previous 
treated for tuberculosis, May 2012 - December 2018.   
Previous episode(s) Last episode (RR-TB) 
Number Year 
(s) 
DST Treatment result Year Treatment 
result 
1 2009 Unknown Lost to follow-up 2012 Cured 
2 2009 Unknown Cured 2012 Cured 
3 2012 RR Lost to follow-up 2013 Lost to follow- 
up 
4 2009 Unknown Cured 2013 Cured 
5 2012 RR Lost to follow-up 2013 Lost to follow- 
up 
6 2000 Unknown Cured 2014 Cured 
7 2013 RR Cured 2014 Cured 





Lost to follow-up 
Cured 
2017 Died 









Lost to follow-up 
Cured 
2017 Lost to follow- 
up 
12 2010 Unknown Cured 2018 Cured 
DST = drug susceptibility test; ND = not determined; RR = rifampicin resistance; 
TB = tuberculosis 
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pyrazinamide for at least two months, was recommended.[21] These 
guidelines also advised a retreatment regimen with first-line drugs and 
streptomycin (“Category 2 regimen”) for patients with relapse or return 
after loss to follow-up. In 2011, WHO published an update stating that 
the detection of rifampicin resistance by Xpert test usually suffices to 
prescribe second-line TB regimen [22], but also cautioned for situations 
in which the Xpert test has a low predictive value and advised that re-
sults need to be confirmed by phenotypic DST or line probe assay. The 
update also noted that a potential harm from placing all rifampicin- 
resistant patients on an MDR-TB regimen, was the exclusion of isoni-
azid from their treatment, thus depriving them of a safe and useful 
bactericidal drug.[22] A systematic review in 2016 identified only three 
studies reporting treatment outcomes for patients with RR-TB, pre-
venting a meta-analysis.[23] Since 2016, WHO guidelines on drug- 
resistant TB recommend similar treatment regimens for patients with 
RR-TB and MDR-TB.[3,24] The guideline for treatment of TB and RR/ 
MDR-TB in Suriname was updated following these latest recommenda-
tions of the WHO, and does not include ciprofloxacin and streptomycin 
anymore because of limited evidence of their effectiveness and steril-
izing activity. 
The clinical relevance of disputed mutations with low-level rifam-
picin resistance has been an issue of debate. One study indicated that 
disputed mutations had the same poor clinical prognosis as the most 
frequent undisputed mutations.[25] Williamson et al. suggested to 
conduct a multi-centre retrospective study to correlate the different 
types of rpoB mutations with clinical outcomes.[18] They stated that the 
retrospective nature of such a study would actually become a method-
ological strength, as it would allow data on treatment outcome to be 
obtained, and thus allow the clinical relevance of mutations to be 
assessed.[18] We consider our observational study to be such a study, 
that contains to our knowledge the largest set of patients infected with 
M. tuberculosis strains carrying the D435Y mutation. Our observation of 
good treatment results of patients with this peculiar type of low-level 
rifampicin resistance and susceptibility for isoniazid, suggests that 
treatment regimens with isoniazid and rifampicin can still be effective. 
The relatively high number of RR-TB cases with previous TB treatment is 
a concern and suggests that a sterilizing effect was not achieved. How-
ever, one-quarter of these patients did not complete the previous 
treatment which obviously contributed to relapse, while reinfection is 
also possible in an environment with ongoing transmission. 
Several authors have proposed alternative treatment options for 
patients infected with a low-level rifampicin resistance, e.g. a higher 
dose of rifampicin or replacing rifampicin by rifabutin.[10,16,18,20,26] 
The currently recommended dose of rifampicin has been challenged 
over the last years.[27,28] Dosage studies indicate that 35 mg/kg 
rifampicin instead of 10 mg/kg is well tolerated and more effective than 
the standard dose.[29,30] These authors recommend high dose rifam-
picin for patients with TB meningitis, co-infection with HIV, diabetes 
mellitus and serious ill TB patients, since plasma concentrations of 
rifampicin are often too low. Our hypothesis is that patients with low- 
level rifampicin mono-resistant TB could benefit more from a first-line 
regimen, including isoniazid and high dose rifampicin (or rifabutin), 
rather than from a lengthy regimen for RR/MDR-TB treatment or the 
standard TB treatment. We have developed a study to treat these pa-
tients accordingly in Suriname and a protocol has been developed and 
cleared by the Human Scientific Research Ethic Committee, and includes 
informed consent of the patient for treatment with high-dose rifampicin 
(30 mg/kg); timely WGS testing of all RR-isolates; measuring of rifam-
picin blood levels; close supervision of treatment, including monitoring 
of side effects; case discussion in a Concilium; and a minimal follow-up 
of one year after treatment. 
Our study also revealed several other issues, some beyond the scope 
of this study. All examined isolates of RR-TB patients, both found in 
Suriname and the Netherlands, belonged by WGS genetically to one 
large molecular transatlantic cluster. Transmission of the rifampicin- 
resistant strain is likely to be ongoing in Suriname, and possibly also 
in the Netherlands. Second, the observed TB/HIV co-infection rate 
(23%) is one of the highest in the WHO Region of the Americas [1]. More 
TB/HIV collaborative efforts are needed to control TB and move towards 
TB elimination in Suriname. RR-TB was more often detected in Creole 
people, which is also the ethnic group with a very high TB incidence, 
HIV co-infection rates and illicit drug use. Our data show a high TB case 
fatality of 14%, which has been associated with higher age and HIV co- 
infection.[31] 
Our study had several strengths and limitations. We made use of a 
detailed electronic database and advanced molecular tests were applied 
on a subset of rifampicin-resistant M. tuberculosis isolates, although not 
all rifampicin-resistant isolates were available for additional typing. The 
100% concordance of rifampicin resistance found by Xpert in Suriname 
and by WGS done in the Netherlands, confirmed that these patients 
actually had RR-TB. The major limitation of our study is that RR-TB 
patients were not actively followed up for recurrent TB after treatment 
completion. We will address this issue in the planned prospective study. 
Our analysis did not include rifampicin-susceptible isolates. Recently, 
we analysed another 118 lysates, including 18 rifampicin-resistant 
strains of patients diagnosed in 2018–2020. All rifampicin-resistant 
isolates had the D435Y mutation; none of the other strains carried mu-
tations in the katG or inhA genes or had other first-line drug resistance- 
Table 5 
Patients with Mycobacterium tuberculosis isolates with a D435Y mutation in the Netherlands, 2003–2018.  
Number Year Country/region of birth Drug-susceptibility test results Treatment regimen    
INH RIF (MIC) RIF(MGIT; 1 mg/l) RBT  
1. 2003 Eastern-Europe R R (>5 mg/L) ND S 2nd line + RBT 
2. 2003 Netherlands R R (2 mg/L) ND S 2nd line + RBT 
3. 2003 European Union R R (2 mg/L) ND S 2nd line + RBT 
4. 2005 a Suriname S R (2 mg/L) ND ND 1st line (without RIF/RBT) + moxifloxacin 
5. 2006 Netherlands R S (0.5 mg/L) ND S 1st line (including standard dose RIF) + moxifloxacin 
6. 2010 a Suriname S ND S ND 1st line (including standard dose RIF) 
7. 2011 European Union R R (2 mg/L) R S 2nd line + RBT 
8. 2011 Africa R R (2 mg/L) ND S 2nd line + RBT 
9. 2012 Africa R R (2 mg/L) ND R 2nd line (without RIF/RBT) 
10. 2012 a Suriname S ND S ND 1st line (including standard dose RIF) 
11. 2013 Asia R ND R b R b 2nd line (without RIF/RBT) 
12. 2014 a Suriname S R (2 mg/L) ND S 1st line (including RBT) 
13. 2016 Eastern-Europe R ND S S 2nd line + RBT 
14. 2016 Africa R S (0.5 mg/L) S S 2nd line + high dose RIF 
15. 2017 a Suriname S R (5 mg/L) S S 1st line (including RBT) 
Abbreviations: INH = isoniazid; MGIT = Mycobacteria Growth Indicator Tube; MIC = minimal inhibitory concentration (by Middlebrook 7H10 agar proportion 
method); ND = not determined; R = resistant; RBT = rifabutin; RIF = rifampicin; S = susceptible. 
a Patients 4, 6, 10, 12 and 15 had clustering M. tuberculosis isolates in Whole Genome Sequencing (≤12 single nucleotide polymorphism difference). 
b The M. tuberculosis isolate had two mutations in the rpoB gene, i.e. D435Y and S450L. 
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associated mutations. 
The findings of our study provide clarity to the rifampicin resistance 
situation in Suriname and possible implications for tailored treatment 
regimens. Our study shows that an epidemic of RR-TB was driven by a 
mutation of which the clinical significance is disputed. All but one 
strains examined revealed low-level rifampicin resistance and isoniazid 
susceptibility. Treatment results with rifampicin-containing regimens 
were unexpectedly good. Further research is needed to study alternative 
treatment options for these patients, such as regimens with high dose 
rifampicin for these specific group of patients, with systematic follow-up 
after treatment completion. We state that one size does not fit all for the 
treatment of RR/MDR-TB, i.e. some people need XL (extra-large) and 
others XS (extra-small) treatment regimens, depending on the causative 
strain. Technological advances make it increasingly possible to tailor 
treatment to the patient and their bacteria. Furthermore, collaborative 
networks of professionals and countries with different resources can 
work together to provide the necessary scientific evidence for effective 
XL or XS RR/MDR-TB treatment regimens. In the end, we want to pro-
vide each patient the right treatment, not too much and not too little, a 
concept of stratified medicine also advocated for the treatment of TB. 
[32] 
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